Entero Therapeutics Profit Margin

Entero Therapeutics's profit margin stands at -4961.87% as of June 2026. That compares with 15083.24% in the prior-year period — down 132.9% year over year. That is below the Healthcare sector average of 9.71%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Entero Therapeutics reported -4961.87% in profit margin versus 15083.24% a year earlier — a 132.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Entero Therapeutics sits lower the Healthcare benchmark (9.71%) with a profit margin of -4961.87%. That is roughly 51221.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -4961.87% for Entero Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Entero Therapeutics's profit margin evolved across reporting periods, while the comparison chart places ENTO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.